Diagnosis and management of synovial sarcoma

R. Lor Randall, Kathryn Schabel, Ying Hitchcock, David E. Joyner, Karen H. Albritton

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Synovial sarcoma is a unique tumor with substantial promise for biologically targeted therapy. Although it demonstrates moderate chemosensitivity, with approximately 50% response rates to ifosfamide- and doxorubicin-containing regimens, it has a diagnostic translocation and a potentially informative chimeric protein product. Although surgical management remains the cornerstone to effect local control, therapeutic advancements are unlikely to occur by continuing to include advanced cases of synovial sarcomas in trials with other soft tissue sarcomas. Rather, attention should be turned toward prospective molecular targets and development of novel agents to exploit them. Research should be directed at understanding the fusion protein of the X,18 translocation and further validating the role of overexpressed proteins in synovial sarcoma. Meanwhile, carefully designed clinical trials of these agents, with translational correlates, will provide in vivo data to complement the preclinical experience.

Original languageEnglish (US)
Pages (from-to)449-459
Number of pages11
JournalCurrent Treatment Options in Oncology
Volume6
Issue number6
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Synovial Sarcoma
Ifosfamide
Proteins
Sarcoma
Doxorubicin
Clinical Trials
Therapeutics
Research
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lor Randall, R., Schabel, K., Hitchcock, Y., Joyner, D. E., & Albritton, K. H. (2005). Diagnosis and management of synovial sarcoma. Current Treatment Options in Oncology, 6(6), 449-459. https://doi.org/10.1007/s11864-005-0024-z

Diagnosis and management of synovial sarcoma. / Lor Randall, R.; Schabel, Kathryn; Hitchcock, Ying; Joyner, David E.; Albritton, Karen H.

In: Current Treatment Options in Oncology, Vol. 6, No. 6, 11.2005, p. 449-459.

Research output: Contribution to journalArticle

Lor Randall, R, Schabel, K, Hitchcock, Y, Joyner, DE & Albritton, KH 2005, 'Diagnosis and management of synovial sarcoma', Current Treatment Options in Oncology, vol. 6, no. 6, pp. 449-459. https://doi.org/10.1007/s11864-005-0024-z
Lor Randall, R. ; Schabel, Kathryn ; Hitchcock, Ying ; Joyner, David E. ; Albritton, Karen H. / Diagnosis and management of synovial sarcoma. In: Current Treatment Options in Oncology. 2005 ; Vol. 6, No. 6. pp. 449-459.
@article{0f6aca2a1f064ea5b831a46b00b4db23,
title = "Diagnosis and management of synovial sarcoma",
abstract = "Synovial sarcoma is a unique tumor with substantial promise for biologically targeted therapy. Although it demonstrates moderate chemosensitivity, with approximately 50{\%} response rates to ifosfamide- and doxorubicin-containing regimens, it has a diagnostic translocation and a potentially informative chimeric protein product. Although surgical management remains the cornerstone to effect local control, therapeutic advancements are unlikely to occur by continuing to include advanced cases of synovial sarcomas in trials with other soft tissue sarcomas. Rather, attention should be turned toward prospective molecular targets and development of novel agents to exploit them. Research should be directed at understanding the fusion protein of the X,18 translocation and further validating the role of overexpressed proteins in synovial sarcoma. Meanwhile, carefully designed clinical trials of these agents, with translational correlates, will provide in vivo data to complement the preclinical experience.",
author = "{Lor Randall}, R. and Kathryn Schabel and Ying Hitchcock and Joyner, {David E.} and Albritton, {Karen H.}",
year = "2005",
month = "11",
doi = "10.1007/s11864-005-0024-z",
language = "English (US)",
volume = "6",
pages = "449--459",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Diagnosis and management of synovial sarcoma

AU - Lor Randall, R.

AU - Schabel, Kathryn

AU - Hitchcock, Ying

AU - Joyner, David E.

AU - Albritton, Karen H.

PY - 2005/11

Y1 - 2005/11

N2 - Synovial sarcoma is a unique tumor with substantial promise for biologically targeted therapy. Although it demonstrates moderate chemosensitivity, with approximately 50% response rates to ifosfamide- and doxorubicin-containing regimens, it has a diagnostic translocation and a potentially informative chimeric protein product. Although surgical management remains the cornerstone to effect local control, therapeutic advancements are unlikely to occur by continuing to include advanced cases of synovial sarcomas in trials with other soft tissue sarcomas. Rather, attention should be turned toward prospective molecular targets and development of novel agents to exploit them. Research should be directed at understanding the fusion protein of the X,18 translocation and further validating the role of overexpressed proteins in synovial sarcoma. Meanwhile, carefully designed clinical trials of these agents, with translational correlates, will provide in vivo data to complement the preclinical experience.

AB - Synovial sarcoma is a unique tumor with substantial promise for biologically targeted therapy. Although it demonstrates moderate chemosensitivity, with approximately 50% response rates to ifosfamide- and doxorubicin-containing regimens, it has a diagnostic translocation and a potentially informative chimeric protein product. Although surgical management remains the cornerstone to effect local control, therapeutic advancements are unlikely to occur by continuing to include advanced cases of synovial sarcomas in trials with other soft tissue sarcomas. Rather, attention should be turned toward prospective molecular targets and development of novel agents to exploit them. Research should be directed at understanding the fusion protein of the X,18 translocation and further validating the role of overexpressed proteins in synovial sarcoma. Meanwhile, carefully designed clinical trials of these agents, with translational correlates, will provide in vivo data to complement the preclinical experience.

UR - http://www.scopus.com/inward/record.url?scp=29844455078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29844455078&partnerID=8YFLogxK

U2 - 10.1007/s11864-005-0024-z

DO - 10.1007/s11864-005-0024-z

M3 - Article

VL - 6

SP - 449

EP - 459

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 6

ER -